




>>Entry Name: Eptifibatide, INN

Synonym(s): Integrilin



CAS Registry Number: 148031-34-9

Molecular Formula: C₃₅H₄₉N₁₁O₉S₂

Molecular Weight: 831.972

Accurate Mass: 831.315614

Percentage Composition: C 50.53%; H 5.94%; N 18.52%; O 17.31%; S 7.71%

General Statement: Synth. cyclic heptapeptide

Biological Use/Importance: Platelet aggregation inhibitor. Fibrinogen (glycoprotein IIb/IIIa) receptor antagonist

Development Status: Marketed drug. Launched 1998 (US). Approved for use in the EU and by FDA (1999)

References:

- Scarborough, R.M. *et al.*, *J. Biol. Chem.*, 1993, **268**, 1066-1073, (*synth, activity*)
Nicoline, F.A. *et al.*, *Circulation*, 1994, **89**, 1802-1809, (*pharmacol*)
Uthoff, K. *et al.*, *Circulation*, 1994, **90**, II269-II274, (*pharmacol*)
Tcheng, J.E., *Am. Heart J.*, 1995, **130**, 673-679; 2000, **139**, S38-S45, (*rev*)
Harrington, R.A. *et al.*, *Am. J. Cardiol.*, 1995, **76**, 1222-1227, (*pharmacokinet*)
Ohman, E.M. *et al.*, *Eur. Heart J.*, 1995, **16**, 50-55, (*rev*)
Schulman, S.P. *et al.*, *Circulation*, 1996, **94**, 2083-2089, (*pharmacol*)
White, H.D., *Am. J. Cardiol.*, 1997, **80**, 1B-48B, (*pharmacol, clin trials, rev*)
Alton, K.B. *et al.*, *Clin. Ther.*, 1998, **20**, 307-323, (*metab*)
Scarborough, R.M., *Drugs of the Future*, 1998, **23**, 585-590, (*rev*)
Goa, K.L. *et al.*, *Drugs*, 1999, **57**, 439-462, (*rev*)
O'Shea, J.C., *Expert Opin. Invest. Drugs*, 1999, **8**, 1893-1905, (*rev*)
Martindale, The Extra Pharmacopoeia, 32nd edn., *Pharmaceutical Press*, 1999, 865